Tymlos (Abaloparatide) Injections for Women 65 and Older: A Caregiver's Complete Administration Guide

Why Abaloparatide Matters More as Women Age

Osteoporosis is not an equal-opportunity disease. Women account for approximately 80% of all osteoporosis cases in the United States, and fracture risk does not plateau after 65. It keeps climbing. Hip fracture incidence roughly doubles every decade after age 50, and a woman who fractures a hip at 75 faces a one-year mortality risk of up to 24%.

Abaloparatide works differently from bisphosphonates or denosumab. It is an anabolic agent, meaning it builds new bone rather than simply slowing breakdown. The drug mimics parathyroid hormone-related protein (PTHrP) and selectively activates the PTH1 receptor in a conformational state that favors bone formation over resorption. That mechanism matters in older women whose bone-formation machinery has slowed for years after estrogen withdrawal.

The ACTIVE Trial: What the Data Actually Show in Older Women

The key ACTIVE trial enrolled 2,463 postmenopausal women with osteoporosis across 28 countries. The mean age was 69 years. Over 18 months, abaloparatide 80 mcg daily reduced new vertebral fractures by 86% compared with placebo (0.58% vs. 4.22%, p < 0.001) and reduced nonvertebral fractures by 43% compared with placebo (2.7% vs. 4.7%, p = 0.049). The active comparator arm (teriparatide 20 mcg) reduced vertebral fractures by 80% versus placebo, so abaloparatide performed at least as well in head-to-head fracture-endpoint comparison.

A subgroup analysis of women aged 65 and older showed consistent benefit. That age group made up the majority of the trial population, so the trial data are not extrapolated from younger cohorts.

Why Self-Injection Becomes Harder With Age

Daily subcutaneous injection requires fine motor control, adequate grip strength, consistent vision, and reliable memory. Each of these may decline after 65 from arthritis, essential tremor, cataracts, or cognitive changes. A caregiver taking over the injection does not reduce the drug's effectiveness. What matters is technique consistency, not who holds the pen.

Understanding the Abaloparatide Pen Before You Begin

The Tymlos pen delivers a fixed 80 mcg dose in each 40-microliter injection. You cannot adjust the dose. The pen contains 30 doses, which is a 30-day supply for one person.

What Is in the Box

Each new prescription includes the prefilled multidose pen and a package insert. Needles are not included. Your pharmacy or specialty pharmacy will provide BD Ultra-Fine pen needles or equivalent 31-gauge, 5 mm (3/16 inch) needles separately. Confirm with the dispensing pharmacy that compatible needles are available before the patient's first injection day.

Checking the Pen Before Every Use

Before each injection, look at the liquid through the pen window. It should be clear and colorless. Do not use the pen if the liquid is cloudy, discolored, or contains particles. Check the expiration date on the pen label. Discard and replace any pen that has been at room temperature for more than 30 days, even if doses remain.

Step-by-Step Caregiver Injection Technique

The following framework reflects the FDA-approved prescribing information and clinical pharmacy guidance for caregiver-administered subcutaneous injections in older adults. It is organized into five phases so that a caregiver can use it as a checklist.

Phase 1: Prepare the Environment (5 Minutes Before)

Choose a time of day you can repeat every day. Morning after breakfast works well because the patient is already sitting upright, which matters for orthostatic hypotension monitoring. Lay out on a clean surface: the Tymlos pen, a new pen needle in its outer cap, an alcohol swab, a cotton ball or gauze, and a sharps container.

Wash your hands with soap and water for 20 seconds. Dry them completely. Wet hands reduce grip on the pen.

If this is a brand-new pen, remove the pen cap and check the black dosing button at the bottom. It should be fully retracted (flush with the pen body). If the button is already extended, the pen has been used. Do not prime a pen that has already been primed and used.

Phase 2: Prime the Pen (New Pen Only, First Use)

1. Attach a new needle by twisting it clockwise onto the pen tip until snug. Do not overtighten.
2. Remove both the outer needle cap and the inner needle cap. Keep the outer cap to remove the needle after the injection.
3. Point the pen with the needle facing up.
4. Press and hold the black dosing button for 5 seconds while watching the inspection window. A small stream or droplet of liquid should appear at the needle tip. This confirms the pen is primed and ready.
5. If no liquid appears, repeat the priming step once more. If it still fails, contact the specialty pharmacy or Radius Health patient support.

You prime the pen only once on the first day of a new pen. On all subsequent days with the same pen, skip directly to Phase 3.

Phase 3: Choose and Prepare the Injection Site

The FDA-approved injection site for abaloparatide is the periumbilical abdomen, the area around the navel. Unlike insulin or some other injectables, the thighs and upper arms are not approved alternative sites. Stay at least 2 inches from the navel itself and avoid scars, bruises, stretch marks, and areas where skin is broken or irritated.

Rotate the site systematically. A simple pattern: divide the abdomen into four quadrants and cycle clockwise each day. Keep a small log if the patient's memory makes tracking difficult.

Clean the chosen spot with an alcohol swab using a circular outward motion. Allow 10 to 15 seconds for the alcohol to dry completely. Injecting into wet skin stings more and may introduce alcohol into the subcutaneous space.

Phase 4: Give the Injection

Gently pinch about 1 to 2 inches of skin and subcutaneous tissue between your thumb and forefinger. Hold the Tymlos pen perpendicular to the skin surface (90-degree angle). Press the needle tip against the skin and push in until the needle is fully inserted.

Press and hold the black dosing button firmly. Hold it down and count slowly to 10 seconds. This is longer than many insulin pens require, and the 10-second hold is necessary to deliver the full dose. Releasing the button before 10 seconds will result in an incomplete dose.

After 10 seconds, withdraw the pen straight out without tilting. Apply gentle pressure with a cotton ball or gauze for a few seconds. Do not rub. Rubbing does not prevent bruising and can increase local irritation.

Phase 5: Dispose and Monitor

Replace the outer needle cap over the needle using the one-hand scoop method (place the cap on a flat surface, slide the needle into it, then twist off). Drop the entire capped needle into the sharps container. Never recap with two hands or leave an uncapped needle on the counter.

Recap the Tymlos pen and store it at room temperature (up to 77 degrees Fahrenheit, 25 degrees Celsius) for the remainder of the 30-day in-use period. Do not refrigerate the pen once it has been opened and used.

Have the patient remain seated or lying down for at least 4 hours. See the orthostatic hypotension section below.

Managing Orthostatic Hypotension in Women 65+

Orthostatic hypotension (a drop in blood pressure when standing) is the most clinically significant acute side effect of abaloparatide in older women. In the ACTIVE trial, dizziness occurred in 10.1% of the abaloparatide group versus 6.0% in the placebo group, and most episodes were tied to standing too quickly after injection.

Why Older Women Are at Higher Risk

Blood pressure regulation changes with age. Baroreceptor sensitivity declines, venous return slows, and many women 65 and older are also taking antihypertensives, diuretics, or alpha-blockers for other conditions. Abaloparatide causes a transient vasodilatory effect in the first few hours after injection. In a woman already on amlodipine or hydrochlorothiazide, that transient effect can produce a meaningful symptomatic drop.

The 4-Hour Rule in Practice

After injection, the patient should sit in a chair or recline in bed for at least 4 hours. If she needs to get up during that window, she should sit at the edge of the seat for 30 seconds before standing, then stand slowly while holding a stable surface. A grab bar or sturdy chair back is ideal. Tell caregivers specifically: do not leave the patient alone to walk to the bathroom immediately after injection without assistance during the 4-hour window.

If dizziness or near-fainting occurs, have the patient sit or lie down immediately. Place cool water on her wrists or the back of her neck. If she loses consciousness or the episode lasts more than a few minutes, call emergency services.

Side Effects Caregivers Must Know About

Beyond orthostatic hypotension, there are several reactions a caregiver should be able to recognize.

Injection-site reactions are common. Redness, bruising, and mild swelling at the injection site occur in roughly 58% of patients at some point during treatment. Most reactions resolve within a few hours. Rotating sites consistently reduces cumulative local irritation. If a site becomes warm, significantly swollen, or develops streaking, contact the prescriber.

Hypercalcemia is a theoretical concern with any anabolic bone agent. In the ACTIVE trial, hypercalcemia occurred in 2.9% of the abaloparatide group. Symptoms include nausea, constipation, fatigue, or confusion. If the patient already takes calcium supplements exceeding 1,000 mg daily or has a history of hypercalciuria, the prescriber should have reviewed supplement levels before starting. As a caregiver, watch for unexplained nausea or new confusion and report it promptly.

Tachycardia (fast heart rate) was noted in 2.1% of the abaloparatide group versus 1.0% in placebo. If the patient reports palpitations or the caregiver notices an unusually rapid pulse in the hour after injection, document it and notify the prescriber.

Osteosarcoma risk. The prescribing information carries a boxed warning about osteosarcoma risk, based on rat studies using doses 4 to 28 times the human dose over the rodents' lifetime. No cases of abaloparatide-induced osteosarcoma have been reported in human clinical trial participants. However, this is why lifetime use is capped at 2 years and why the drug is contraindicated in patients with prior radiation therapy to the skeleton, Paget's disease, unexplained elevated alkaline phosphatase, or open epiphyses.

Pregnancy and Lactation: What Caregivers Need to Know

Abaloparatide is indicated exclusively for postmenopausal women. By definition, postmenopausal means no menstrual period for 12 consecutive months due to the permanent cessation of ovarian function, not surgical menopause alone in a woman who might otherwise still conceive.

Abaloparatide is classified Pregnancy Category X equivalent under current FDA labeling: it is contraindicated in pregnancy. Animal studies show fetal harm at doses below the human therapeutic range. There are no adequate human pregnancy data and none will be gathered, given the indication. If a caregiver is ever administering this drug to a woman who could theoretically be premenopausal (for example, a woman who had early surgical menopause but retains the theoretical possibility of conception), the prescribing clinician must confirm and document that reliable contraception is in place. In practice, patients 65 and older are well past this concern, but the contraindication stands in principle.

Lactation transfer has not been studied. Abaloparatide is not indicated in women who are breastfeeding, and no data exist on milk transfer in humans. Given the indication is postmenopausal osteoporosis, lactation is not an expected clinical scenario in this population.

Who This Drug Is Right For (and Who Should Not Use It)

Women Most Likely to Benefit

Abaloparatide is appropriate for postmenopausal women with at least one of the following: a T-score of -2.5 or lower, a prior fragility fracture (vertebral or hip), or very high fracture risk as defined by FRAX 10-year major osteoporotic fracture probability exceeding 20%. The American College of Obstetricians and Gynecologists Practice Bulletin 129 supports anabolic therapy as first-line for very high-risk individuals rather than reserving it as a second-line option after bisphosphonate failure.

Women 65 and older who have had a spine or hip fracture, who have been on long-term glucocorticoids, or who have not responded to bisphosphonates are particularly strong candidates. The anabolic mechanism provides a bone-density benefit that antiresorptives alone cannot achieve in this subgroup.

Women Who Should Not Use Abaloparatide

The following are contraindications or situations where a different therapy is typically chosen.

• Prior radiation therapy to the skeleton.
• Paget's disease of bone or unexplained elevated alkaline phosphatase.
• Pre-existing hypercalcemia.
• Severe renal impairment (creatinine clearance <30 mL/min; data are limited and the prescriber should weigh risk carefully per the label).
• Prior osteosarcoma or bone malignancy.
• Pregnancy (as discussed above).

Women with a history of kidney stones should discuss calcium and vitamin D supplement levels with the prescriber before starting, since hypercalciuria is a known risk.

The 2-Year Limit and What Comes After

Abaloparatide is approved for a maximum of 24 months of cumulative lifetime use. This is not a soft guideline; it is a hard cap built into the boxed warning. Once the 24-month course ends, the bone gains must be preserved with sequential antiresorptive therapy.

The ACTIVExtend trial followed patients who completed 18 months of abaloparatide and then transitioned to alendronate 70 mg weekly for 24 months. The combined sequence produced a 6.7% increase in lumbar spine BMD and a 4.8% increase in total hip BMD from abaloparatide baseline. Vertebral fracture risk remained significantly reduced through the full sequential period compared with placebo-to-alendronate. This trial provides direct evidence that the anabolic-then-antiresorptive sequence works in postmenopausal women of this age group.

The prescriber will schedule a DXA scan at or near the end of the abaloparatide course to document BMD gains before selecting the follow-on therapy. Caregivers should make sure the patient does not miss this appointment. Stopping abaloparatide without transitioning to an antiresorptive leads to rapid reversal of BMD gains, often within 12 months.

Practical Storage and Pen Logistics for Caregivers

Storage is a common source of error in older patients who rely on caregivers. The rules are straightforward but specific.

Before first use: Store the pen in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Do not freeze. Do not store in the door of the refrigerator where temperature fluctuates with opening. Do not leave the pen in a car, even briefly in moderate weather.

After first use: Keep the pen at room temperature, up to 77 degrees Fahrenheit (25 degrees Celsius), for up to 30 days. Do not put it back in the refrigerator once started. Mark the date of first use on the pen label with a permanent marker.

If a dose is missed: Inject it as soon as possible on the same day. If the missed day has passed (it is already the next calendar day), skip the missed dose entirely and resume the usual schedule the following day. Do not inject two doses in one day.

If the pen is dropped: Check the inspection window for cloudiness or damage. If the liquid appears normal and the pen mechanism still clicks properly, the dose can be given. If you are uncertain, contact the pharmacy.

Communicating With the Care Team

Caregivers are often the earliest observers of side effects. Keep a brief daily log for the first 30 days. Note the time of injection, any immediate reactions (redness, dizziness, nausea), and any new symptoms in the hours after. Bring this log to every follow-up appointment.

The prescriber will typically schedule a follow-up 4 to 6 weeks after starting abaloparatide to check serum calcium, check for side effects, and review injection technique. If the patient is seen by a visiting nurse or home health aide, that clinician can also assess injection sites and document concerns.

"In women over 70, the absolute fracture risk reduction from anabolic therapy is proportionally larger than in younger postmenopausal women, precisely because the baseline risk is so much higher," notes Rachel Goldberg, MD, a board-certified OB-GYN and WomanRx medical reviewer. "A caregiver who gives these injections reliably and correctly is genuinely preventing disability and death, not just managing a lab value."

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis states that anabolic therapy should be considered as initial treatment for patients at very high fracture risk, rather than reserved for those who fail antiresorptive therapy first. Caregivers who understand the purpose of the medication are more likely to maintain consistency.

Coordinating With Other Medications

Abaloparatide does not have known drug-drug interactions that require dose adjustment. However, in women 65 and older who may take 5 to 10 daily medications, a few practical points deserve attention.

Calcium and vitamin D supplementation should continue alongside abaloparatide. The ACTIVE trial allowed participants to take calcium and vitamin D supplements throughout. The National Osteoporosis Foundation recommends 1,000 to 1,200 mg of calcium daily from all sources combined (food plus supplements) and 800 to 1,000 IU of vitamin D3 daily for women 65 and older. Exceeding 1,500 mg of supplemental calcium daily without medical supervision increases hypercalcemia risk when paired with an anabolic agent.

Antihypertensives increase the orthostatic hypotension risk in the post-injection window. If the patient takes a diuretic, ACE inhibitor, or calcium channel blocker, the 4-hour sitting protocol after injection is especially important. Discuss with the prescriber whether medication timing can be adjusted to separate peak antihypertensive effect from the injection window.

Thyroid medications do not interact directly, but hypothyroidism affects bone turnover markers. If the patient takes levothyroxine, TSH should be checked at baseline and the dose kept at the lowest effective level to avoid over-suppression, which independently increases bone loss.

Evidence Gaps in Women 65+ and What Is Extrapolated

Women 65 and older were well-represented in the ACTIVE trial, and the key fracture reduction data come largely from this group. The trial did not separately power for women over 80, and no dedicated data exist for women with frailty syndromes, those in skilled nursing facilities, or those with moderate to severe cognitive impairment. In these subgroups, caregiver-administered therapy is common in clinical practice, but the evidence is extrapolated from the broader trial population.

Injection-site data come from patients who self-injected. Caregiver injection technique has not been studied in a randomized controlled trial. The assumption is that the pharmacokinetics remain identical when a trained caregiver injects at the correct site and depth, which is pharmacologically reasonable but not directly proven in this drug.

Women with PCOS who transition to postmenopause carry a different metabolic and bone-health history than women without PCOS. Chronic androgen excess and higher body weight in PCOS may partly offset earlier bone protection, but no abaloparatide subgroup data exist for women with prior PCOS. Women with a history of premature ovarian insufficiency (POI) who reach age 65 after years of estrogen deficiency may have more severe baseline osteoporosis and may benefit earlier and more substantially from anabolic therapy, though again this subgroup is not separately analyzed in the ACTIVE data.

When your data are thin, say so plainly. This population needs honest guidance, not false certainty.